Nephrol Dial Transplant (2001) 16: 1262-1266
© 2001 European Renal Association-European Dialysis and Transplant Association
Technical Note
An experimental sclerosing encapsulating peritonitis model in mice
1 Tokyo Women's Medical University, Kidney Center, Department of Surgery and 2 Nippon Medical School, Department of Pathology, Tokyo, Japan
Abstract
Background. Sclerosing encapsulating peritonitis (SEP) is a life-threatening complication of continuous ambulatory peritoneal dialysis. To elucidate the mechanism and develop treatments for this condition, an experimental SEP model in mice was constructed.
Methods. C57BL/6 mice were administered 0.3 ml of 0.1% chlorhexidine gluconate and 15% ethanol dissolved in saline, intraperitoneally, on a daily basis for 56 days (group 1, n=15). A control group of C57BL/6 mice were administered 0.3 ml of phosphate-buffered saline only in the same manner (group 2, n=15). The mice were sacrificed on days 3, 7, 21, 56 and were prepared for histological analysis.
Results. In group 1, all mice had developed macroscopic evidence of SEP 56 days after the injection. Microscopically we observed peritoneal fibrosis and an increase in infiltrates of mononuclear cells over time. The peritoneal fibrosis reached the chronic inflammatory stage by 56 days after the injection.
Conclusion. We have developed a convenient experimental model of SEP in mice, which may be useful in elucidating the pathogenesis of SEP and in establishing possible treatments.
Keywords: chlorhexidine gluconate; ethanol; murine model; peritoneal dialysis; sclerosing encapsulating peritonitis
Notes
Correspondence and offprint requests to: Tokihiko Sawada, Tokyo Women's Medical University, Kidney Center, Department of Surgery, 8-1 Kawata-cho, Shinjuku-ku, Tokyo 162-8666, Japan.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. M. Summers ENCAPSULATING PERITONEAL SCLEROSIS -- HAVE WE FOUND THE PERPETRATOR? Perit. Dial. Int., September 1, 2009; 29(5): 499 - 501. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nakav, L. Kachko, M. Vorobiov, B. Rogachev, C. Chaimovitz, M. Zlotnik, and A. Douvdevani Blocking adenosine A2A receptor reduces peritoneal fibrosis in two independent experimental models Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2392 - 2399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mizuno, Y. Ito, N. Hepburn, T. Mizuno, Y. Noda, Y. Yuzawa, C. L. Harris, B. P. Morgan, and S. Matsuo Zymosan, but Not Lipopolysaccharide, Triggers Severe and Progressive Peritoneal Injury Accompanied by Complement Activation in a Rat Peritonitis Model J. Immunol., July 15, 2009; 183(2): 1403 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Saito, M. Kitamoto, K. Kato, N. Liu, H. Kitamura, K. Uemura, F. Nogaki, T. Takeda, N. Mori, and T. Ono TISSUE FACTOR AND FACTOR V INVOLVEMENT IN RAT PERITONEAL FIBROSIS Perit. Dial. Int., May 1, 2009; 29(3): 340 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sawada, Y. Ishii, I. Nakajima, S. Fuchinoue, K. Kubota, and S. Teraoka AN EXPERIMENTAL MODEL OF ENCAPSULATING PERITONEAL SCLEROSIS Perit. Dial. Int., February 1, 2009; 29(Supplement_2): S49 - S50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bozkurt, E. Hur, B. Ulkuden, M. Sezak, H. Nar, O. Purclutepe, S. Sen, and S. Duman CAN N-ACETYLCYSTEINE PRESERVE PERITONEAL FUNCTION AND MORPHOLOGY IN ENCAPSULATING PERITONEAL SCLEROSIS? Perit. Dial. Int., February 1, 2009; 29(Supplement_2): S202 - S205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Evrenkaya, E. M. Atasoyu, S. Unver, C. Basekim, H. Baloglu, and M. Y. Tulbek Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2423 - 2424. [Full Text] [PDF]
|
|
|
|
|
|
I. Hirahara, Y. Ogawa, E. Kusano, and Y. Asano Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1732 - 1741. [Abstract] [Full Text] [PDF]
|
|